Immacule Lifesciences is the fastest growing One Stop Solution for Injectable, from development to commercial manufacturing of injectable in liquid in aqueous/non-aqueous as well as Lyophilized dosage forms in vial and ampoules in the non-oncology space, with robust terminal sterilisation and aseptically filled injectable capabilities. With a global footprint spanning countries such as the United States, Europe, Australia, and other emerging markets, we are backward integrated in pharmaceutical research and development as well as complex injectable manufacturing. Immacule intends to invest USD50 million in its newly acquired land to expand its drug product manufacturing capacity, thereby serving the industry's pipeline across "various modalities." The expansion will specifically add new freeze-drying capacity.